4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company" or "Adagio")), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced, today provided business updates for third quarter ended September 30, 2024. Recent Business Highlights: Reported total company revenue of $185 thousand in the third quarter of 2024, compared to $41 thousand in the third quarter of 2023. In September 2024, secured CMS coverage (Category B) of the vCLAS™ ultra-low temperature cryoablation catheter as a part of FULCRUM-VT Pivotal IDE study for treatment of drug-resistant ventricular tachycardia (VT) in patients with structural heart disease. In October

Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company")), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that its CEO & President, Olav Bergheim, will present at the Stifel 2024 Healthcare Conference on Monday, November 18, at 9:45 a.m. Eastern Time in New York, NY at the Lotte New York Palace Hotel. A live audio webcast and replay of the presentation may be accessed on the "Investors" section of the company's website at: https://www.adagiomedical.com/. About Adagio Medical Adagio Medical is an early commercial stage medical device company located in Laguna Hills, California focusing on developing innovative cryoablation tec

Adagio Medical Holdings, Inc. (NASDAQ:ADGM, "Adagio Medical", "Adagio" or the "Company"))), a leading innovator in catheter ablation technologies, today announced the completion of the first procedures in FULCRUM-VT U.S. Food and Drug Administration (FDA) Pivotal IDE study of Adagio's VT Cryoablation System. Procedures were performed by Professor William G. Stevenson, MD, at Vanderbilt University Medical Center in Nashville, TN and Dr. J. David Burkhardt at Texas Cardiac Arrhythmias Institute (TCAI) at Austin, TX. FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia, NCT05675865) is a prospective, multi-center, open-label, single-ar

Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company"))), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced its sponsorship and participation in the 19th Annual International Symposium on Ventricular Arrhythmias, to be held at the New York Marriott at the Brooklyn Bridge on October 11-12, 2024. In addition to participating in the commercial exhibition, Adagio's proprietary Ultra-Low Temperature Cryoablation (ULTC) technology will be featured within the scientific program of the Symposium. Presentation Details: Date: October 11, 2024 Time: 4:40 p.m. ET Topic: Cryocure-VT: One-year Results and Next Steps (FULCRUM-VT) Presenter:

Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company"))), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal Obtained the U.S. Food and Drug Administration ("FDA") approval for the FULCRUM-VT Pivotal IDE study Cl

SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)